CoCites: A citation-based method for searching scientific literature

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Times Cited: 167

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
Times Cited: 1231

List of shared articles

Times cited

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.
Boris Draznin, Vanita R Aroda, George Bakris, Gretchen Benson, Florence M Brown, RaShaye Freeman, Jennifer Green, Elbert Huang, Diana Isaacs, Scott Kahan,[...]. Diabetes Care 2022

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021.
. Diabetes Care 2021

410

The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.
Józef Drzewoski, Markolf Hanefeld. Pharmaceuticals (Basel) 2021

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Heeyoung Lee, Se-Eun Park, Eun-Young Kim. J Clin Med 2021

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.
. Diabetes Care 2020

549

Reflections on Diabetes Care at the End of the Second Decade of the 21st Century.
Satish K Garg. Diabetes Technol Ther 2020

Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
Thomas A Zelniker, Eugene Braunwald. J Am Coll Cardiol 2020

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.
. Diabetes Care 2019

533

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019